SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?

Detalhes bibliográficos
Autor(a) principal: Pivatto Júnior,Fernando
Data de Publicação: 2018
Outros Autores: Salla,Rafaela Fenalti, Cé,Lísia Cunha, Biolo,Andréia, Silva,André Luís Ferreira Azeredo da, Führ,Bruno, Amon,Luís Carlos, Blaya,Marina Bergamini, Scheffel,Rafael Selbach
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Journal of Cardiovascular Sciences (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472018000500483
Resumo: Abstract Background: The SAMe-TT2R2 score was introduced to identify atrial fibrillation patients with a high risk of not achieving a good time in therapeutic range (TTR) during vitamin K antagonists (VKA) therapy. Objective: The aim of this study was to evaluate this score in venous thromboembolism (VTE) patients. Patients and methods: A retrospective cohort study of patients receiving care at the outpatient anticoagulation clinic of a tertiary care teaching hospital. Patients were classified as having low (score 0-1) or high risk (score ≥ 2) of not achieving a good TTR. The area under the ROC curve was calculated to assess the ability of the score to predict a TTR ≥ 65%. Adverse event-free survival curves according to the SAMe-TT2R2 score were calculated by the Kaplan-Meier method and compared by the log-rank test. A p-value < 0.05 was considered statistically significant. Results: We investigated 111 patients during a median follow-up of 2.3 (0.7-6.4) years. Mean age was 54.1 ± 15.7 years and 71 (64.0%) were women. Low- and high-risk groups had similar mean TTR (51.9 vs. 49.6%; p = 0.593). The two groups did not differ significantly in the percentage of patients achieving a TTR ≥ 65% (35.6 vs. 25.8%; p = 0.370). The c-statistic was 0.595 (p = 0.113) for TTR ≥ 65%. Adverse event-free survival during anticoagulation was also similar in both groups (p = 0.136). Conclusions: The SAMe-TT2R2 score does not seem to be a useful tool in oral anticoagulation decision-making for patients with VTE and should not be used in this setting.
id SBC-2_99172cb9df5b6023653bc5910ac66572
oai_identifier_str oai:scielo:S2359-56472018000500483
network_acronym_str SBC-2
network_name_str International Journal of Cardiovascular Sciences (Online)
repository_id_str
spelling SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?Venous thrombosisVenous thromboembolismPulmonary embolismAnticoagulantsDecision support techniquesAbstract Background: The SAMe-TT2R2 score was introduced to identify atrial fibrillation patients with a high risk of not achieving a good time in therapeutic range (TTR) during vitamin K antagonists (VKA) therapy. Objective: The aim of this study was to evaluate this score in venous thromboembolism (VTE) patients. Patients and methods: A retrospective cohort study of patients receiving care at the outpatient anticoagulation clinic of a tertiary care teaching hospital. Patients were classified as having low (score 0-1) or high risk (score ≥ 2) of not achieving a good TTR. The area under the ROC curve was calculated to assess the ability of the score to predict a TTR ≥ 65%. Adverse event-free survival curves according to the SAMe-TT2R2 score were calculated by the Kaplan-Meier method and compared by the log-rank test. A p-value < 0.05 was considered statistically significant. Results: We investigated 111 patients during a median follow-up of 2.3 (0.7-6.4) years. Mean age was 54.1 ± 15.7 years and 71 (64.0%) were women. Low- and high-risk groups had similar mean TTR (51.9 vs. 49.6%; p = 0.593). The two groups did not differ significantly in the percentage of patients achieving a TTR ≥ 65% (35.6 vs. 25.8%; p = 0.370). The c-statistic was 0.595 (p = 0.113) for TTR ≥ 65%. Adverse event-free survival during anticoagulation was also similar in both groups (p = 0.136). Conclusions: The SAMe-TT2R2 score does not seem to be a useful tool in oral anticoagulation decision-making for patients with VTE and should not be used in this setting.Sociedade Brasileira de Cardiologia2018-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472018000500483International Journal of Cardiovascular Sciences v.31 n.5 2018reponame:International Journal of Cardiovascular Sciences (Online)instname:Sociedade Brasileira de Cardiologia (SBC)instacron:SBC10.5935/2359-4802.20180044info:eu-repo/semantics/openAccessPivatto Júnior,FernandoSalla,Rafaela FenaltiCé,Lísia CunhaBiolo,AndréiaSilva,André Luís Ferreira Azeredo daFühr,BrunoAmon,Luís CarlosBlaya,Marina BergaminiScheffel,Rafael Selbacheng2018-12-12T00:00:00Zoai:scielo:S2359-56472018000500483Revistahttp://publicacoes.cardiol.br/portal/ijcshttps://old.scielo.br/oai/scielo-oai.phptailanerodrigues@cardiol.br||revistaijcs@cardiol.br2359-56472359-4802opendoar:2018-12-12T00:00International Journal of Cardiovascular Sciences (Online) - Sociedade Brasileira de Cardiologia (SBC)false
dc.title.none.fl_str_mv SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
title SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
spellingShingle SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
Pivatto Júnior,Fernando
Venous thrombosis
Venous thromboembolism
Pulmonary embolism
Anticoagulants
Decision support techniques
title_short SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
title_full SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
title_fullStr SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
title_full_unstemmed SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
title_sort SAMe-TT2R2 Score: A Useful Tool in Oral Anticoagulation Decision-Making for Venous Thromboembolism Patients?
author Pivatto Júnior,Fernando
author_facet Pivatto Júnior,Fernando
Salla,Rafaela Fenalti
Cé,Lísia Cunha
Biolo,Andréia
Silva,André Luís Ferreira Azeredo da
Führ,Bruno
Amon,Luís Carlos
Blaya,Marina Bergamini
Scheffel,Rafael Selbach
author_role author
author2 Salla,Rafaela Fenalti
Cé,Lísia Cunha
Biolo,Andréia
Silva,André Luís Ferreira Azeredo da
Führ,Bruno
Amon,Luís Carlos
Blaya,Marina Bergamini
Scheffel,Rafael Selbach
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pivatto Júnior,Fernando
Salla,Rafaela Fenalti
Cé,Lísia Cunha
Biolo,Andréia
Silva,André Luís Ferreira Azeredo da
Führ,Bruno
Amon,Luís Carlos
Blaya,Marina Bergamini
Scheffel,Rafael Selbach
dc.subject.por.fl_str_mv Venous thrombosis
Venous thromboembolism
Pulmonary embolism
Anticoagulants
Decision support techniques
topic Venous thrombosis
Venous thromboembolism
Pulmonary embolism
Anticoagulants
Decision support techniques
description Abstract Background: The SAMe-TT2R2 score was introduced to identify atrial fibrillation patients with a high risk of not achieving a good time in therapeutic range (TTR) during vitamin K antagonists (VKA) therapy. Objective: The aim of this study was to evaluate this score in venous thromboembolism (VTE) patients. Patients and methods: A retrospective cohort study of patients receiving care at the outpatient anticoagulation clinic of a tertiary care teaching hospital. Patients were classified as having low (score 0-1) or high risk (score ≥ 2) of not achieving a good TTR. The area under the ROC curve was calculated to assess the ability of the score to predict a TTR ≥ 65%. Adverse event-free survival curves according to the SAMe-TT2R2 score were calculated by the Kaplan-Meier method and compared by the log-rank test. A p-value < 0.05 was considered statistically significant. Results: We investigated 111 patients during a median follow-up of 2.3 (0.7-6.4) years. Mean age was 54.1 ± 15.7 years and 71 (64.0%) were women. Low- and high-risk groups had similar mean TTR (51.9 vs. 49.6%; p = 0.593). The two groups did not differ significantly in the percentage of patients achieving a TTR ≥ 65% (35.6 vs. 25.8%; p = 0.370). The c-statistic was 0.595 (p = 0.113) for TTR ≥ 65%. Adverse event-free survival during anticoagulation was also similar in both groups (p = 0.136). Conclusions: The SAMe-TT2R2 score does not seem to be a useful tool in oral anticoagulation decision-making for patients with VTE and should not be used in this setting.
publishDate 2018
dc.date.none.fl_str_mv 2018-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472018000500483
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472018000500483
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/2359-4802.20180044
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia
publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia
dc.source.none.fl_str_mv International Journal of Cardiovascular Sciences v.31 n.5 2018
reponame:International Journal of Cardiovascular Sciences (Online)
instname:Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
instname_str Sociedade Brasileira de Cardiologia (SBC)
instacron_str SBC
institution SBC
reponame_str International Journal of Cardiovascular Sciences (Online)
collection International Journal of Cardiovascular Sciences (Online)
repository.name.fl_str_mv International Journal of Cardiovascular Sciences (Online) - Sociedade Brasileira de Cardiologia (SBC)
repository.mail.fl_str_mv tailanerodrigues@cardiol.br||revistaijcs@cardiol.br
_version_ 1754732625294000128